Aytu BioPharma 2021 Investor Presentation

Specialty pharmaceutical company combining Aytu and Neos operations with a focus on pediatric therapeutics, consumer health products, and rare disease treatments. The company leverages a national specialty salesforce and differentiated formulations to compete in large therapeutic categories including ADHD, with a late-stage pipeline addressing vascular Ehlers-Danlos Syndrome and difficult-to-treat infections.